SCHEMBL963674

SCHEMBL963674

Cc1nn(C)c(-n2ccc3cc(Cl)ccc32)c1C=CC(=O)NS(=O)(=O)C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
NR2F2 P24468 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BRPF1 P55201 2/20 0.38
SCN2B O60939 2/20 0.36
SCN1B Q07699 2/20 0.36
SCN9A Q15858 2/20 0.36
SCN1A P35498 1/20 0.36
MCL1 Q07820 1/20 0.34
AURKA O14965 1/20 0.33
TPX2 Q9ULW0 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
PHGDH O43175 5/20 0.32
NPY5R Q15761 1/20 0.32
AHR P35869 1/20 0.32
MALT1 Q9UDY8 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL963673 1.00 MAPT (0.39) MAPTNR2F2HTTSMN1; SMN2BRPF1
SCHEMBL5111983 0.88 SMN1; SMN2 (0.41) MAPTNR2F2HTTSMN1; SMN2L3MBTL1
SCHEMBL5111968 0.88 SMN1; SMN2 (0.41) MAPTNR2F2HTTSMN1; SMN2L3MBTL1
SCHEMBL962525 0.87 MAPT (0.37) MAPTNR2F2HTTSMN1; SMN2L3MBTL1
SCHEMBL962524 0.87 MAPT (0.37) MAPTNR2F2HTTSMN1; SMN2L3MBTL1
SCHEMBL966295 0.86 HTT (0.36) MAPTNR2F2HTTSMN1; SMN2AHR
SCHEMBL966293 0.86 HTT (0.36) MAPTNR2F2HTTSMN1; SMN2AHR
SCHEMBL965345 0.86 NPY5R (0.41) MAPTNR2F2HTTSMN1; SMN2NPY5R
SCHEMBL965347 0.86 NPY5R (0.41) MAPTNR2F2HTTSMN1; SMN2NPY5R
SCHEMBL966101 0.86 MAPT (0.36) MAPTNR2F2HTTSMN1; SMN2BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 MAPT 4343/4885NR2F2 2010/4885HTT 3376/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG MAPT 4720/4885NR2F2 201/4885HTT 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.